Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 53 articles:
HTML format
Text format



Single Articles


    June 2017
  1. XU L, Fu Y, Li Y, Han X, et al
    Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3355.
    PubMed     Text format     Abstract available


  2. PARK S, Kang BW, Lee SJ, Yoon S, et al
    Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3348.
    PubMed     Text format     Abstract available


  3. ASPESLAGH S, Shailubhai K, Bahleda R, Gazzah A, et al
    Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
    Cancer Chemother Pharmacol. 2017;79:1257-1265.
    PubMed     Text format     Abstract available


    May 2017
  4. MILAKI G, Messaritakis I, Koinis F, Kotsakis A, et al
    Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 May 18. doi: 10.1007/s00280-017-3339.
    PubMed     Text format     Abstract available


  5. CHEN X, Liu L, Guo Z, Liang W, et al
    UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 May 13. doi: 10.1007/s00280-017-3306.
    PubMed     Text format     Abstract available


  6. OKUDA Y, Sato K, Sudo K, Hasegawa Y, et al
    Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Cancer Chemother Pharmacol. 2017;79:1013-1020.
    PubMed     Text format     Abstract available


    April 2017
  7. FUJIWARA T, Kenmotsu H, Naito T, Kawamura T, et al
    The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3324.
    PubMed     Text format     Abstract available


  8. NISHIJIMA-FUTAMI Y, Minami S, Futami S, Koba T, et al
    Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3321.
    PubMed     Text format     Abstract available


  9. LAU YY, Gu W, Lin T, Viraswami-Appanna K, et al
    Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 19. doi: 10.1007/s00280-017-3308.
    PubMed     Text format     Abstract available


  10. XIANG T, Kang X, Gong Z, Bai W, et al
    XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Cancer Chemother Pharmacol. 2017;79:791-800.
    PubMed     Text format     Abstract available


    March 2017
  11. WAKELEE HA, Gettinger S, Engelman J, Janne PA, et al
    A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 28. doi: 10.1007/s00280-017-3283.
    PubMed     Text format     Abstract available


  12. JANG J, Kim HK, Cho BC, Lee KH, et al
    Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3289.
    PubMed     Text format     Abstract available


  13. ZHOU J, Dong F, Cui F, Xu R, et al
    The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3269.
    PubMed     Text format     Abstract available


  14. HATA A, Katakami N, Hattori Y, Tanaka K, et al
    Pemetrexed monotherapy for chemo-naive elderly (aged >/=80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
    Cancer Chemother Pharmacol. 2017 Mar 9. doi: 10.1007/s00280-017-3259.
    PubMed     Text format     Abstract available


  15. KASHIWABARA K, Semba H, Fujii S, Tsumura S, et al
    Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Cancer Chemother Pharmacol. 2017 Mar 3. doi: 10.1007/s00280-017-3261.
    PubMed     Text format     Abstract available


  16. MORCOS PN, Bogman K, Hubeaux S, Sturm-Pellanda C, et al
    Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
    Cancer Chemother Pharmacol. 2017;79:559-568.
    PubMed     Text format     Abstract available


    February 2017
  17. IMAI H, Kuwako T, Kaira K, Masuda T, et al
    Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Feb 6. doi: 10.1007/s00280-016-3232.
    PubMed     Text format     Abstract available


    January 2017
  18. SHIMIZU T, Yonesaka K, Hayashi H, Iwasa T, et al
    Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jan 31. doi: 10.1007/s00280-016-3231.
    PubMed     Text format     Abstract available


  19. TABCHI S, Blais N, Campeau MP, Tehfe M, et al
    Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jan 12. doi: 10.1007/s00280-016-3226.
    PubMed     Text format     Abstract available


    December 2016
  20. KAIRA K, Tomizawa Y, Imai H, Sakurai R, et al
    Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  21. IMAI H, Kaira K, Naruse I, Hayashi H, et al
    Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  22. GARRETT M, Taylor T, Mould DR, Amantea MA, et al
    Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  23. ZHAO J, Ye X, Xu Y, Chen M, et al
    EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  24. FUKAE M, Shiraishi Y, Hirota T, Sasaki Y, et al
    Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  25. ODA N, Hotta K, Yoshioka H, Kudo K, et al
    Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  26. KUBO T, Fujiwara K, Hotta K, Okada T, et al
    A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  27. ZANG H, Wang W, Fan S
    The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  28. MADAN A, Jones BS, Bordoni R, Saleh MN, et al
    Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  29. YAMADA K, Ichiki M, Takahashi K, Hisamatsu Y, et al
    A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  30. OKUMA Y, Hosomi Y, Takahashi S, Nakahara Y, et al
    A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  31. MIZOGUCHI K, Nakamura Y, Sano K, Sato S, et al
    Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  32. MATIKAS A, Kentepozidis Nu, Ardavanis A, Vaslamatzis M, et al
    Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  33. ZOU T, Yin J, Zheng W, Xiao L, et al
    Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  34. SEKINE A, Satoh H, Baba T, Ikeda S, et al
    Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  35. OZAWA Y, Akahori D, Koda K, Abe T, et al
    Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  36. GUPTA A, Hussein Z, Hassan R, Wustner J, et al
    Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
    Cancer Chemother Pharmacol. 2016;77:733-43.
    PubMed     Text format     Abstract available


    March 2016
  37. KUDO K, Hotta K, Bessho A, Nogami N, et al
    Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  38. KARAYAMA M, Inui N, Kusagaya H, Suzuki S, et al
    Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  39. YOSHIBA S, Jansen M, Matsushima N, Chen S, et al
    Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  40. KONTOPODIS E, Kotsakis A, Kentepozidis N, Syrigos K, et al
    A phase II, open-label trial of bortezomib (VELCADE) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  41. YOSHIMURA Y, Kurasawa M, Yorozu K, Puig O, et al
    Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Cancer Chemother Pharmacol. 2016;77:623-8.
    PubMed     Text format     Abstract available


  42. LUKE JJ, LoRusso P, Shapiro GI, Krivoshik A, et al
    ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
    Cancer Chemother Pharmacol. 2016;77:549-58.
    PubMed     Text format     Abstract available


    February 2016
  43. TRAFALIS DT, Alifieris C, Stathopoulos GP, Sitaras N, et al
    Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  44. ZHANG Q, Sun T, Kang P, Qian K, et al
    Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  45. TAKAGI Y, Hosomi Y, Nagamata M, Watanabe K, et al
    Phase II study of oral vitamin B supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  46. HEO SJ, Jung I, Lee CK, Kim JH, et al
    A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  47. RAJAGOPALAN P, Alahmari KA, Elbessoumy AA, Balasubramaniam M, et al
    Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  48. STROH M, Green M, Cha E, Zhang N, et al
    Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  49. KUMAR R, Lu SK, Minchom A, Sharp A, et al
    A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  50. ARBITRIO M, Di Martino MT, Barbieri V, Agapito G, et al
    Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  51. TOLCHER AW, LoRusso P, Arzt J, Busman TA, et al
    Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2015;76:1025-32.
    PubMed     Text format     Abstract available


  52. MORGAN RJ, Synold TW, Longmate JA, Quinn DI, et al
    Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Cancer Chemother Pharmacol. 2015;76:897-907.
    PubMed     Text format     Abstract available


    September 2015
  53. MLAK R, Krawczyk P, Ciesielka M, Homa I, et al
    Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
    Cancer Chemother Pharmacol. 2015;76:621-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: